That's why we think cancer is such a difficult disease to fight. We believe that in combination with other treatments, our treatment is going to make a big difference for a lot of patients.
Dallas, Texas (PRWEB) February 22, 2013
During the recent FSX Investment Conference held in Dallas, Texas, Galectin Therapeutics Executive Chairman of the Board, Jim Czirr, granted an exclusive interview for FSXInterlinkedTV , an on demand Web Channel dedicated to Entrepreneurs and Investors.
Galectin Therapeutics, (formerly Pro-Pharmaceuticals) is development company, that engages in the discovery and development of therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases. In 2012 they hosted a symposium in Boston attended by scientists from all over the United States, Spain, England, Italy, Germany and South America.
During the Exclusive Interview for FSXInterlinkedTV Czirr stated that Galectin Therapeutics currently has a drug that they are waiting the FDA to approve for Clinical Trial that reverses cirrhosis of the liver and would be used to treat fatty liver disease and NASH. Non-alcoholic steatohepatitisa (NASH) is a liver disease characterized by the accumulation of fat in the liver with associated inflammation and fibrosis which can lead to end-stage cirrhosis requiring liver transplantation. Czirr stated this would address a huge need as "today there is no drug for cirrhosis or for fatty liver disease." This drug that reverses fibrosis in the liver also shows an effect against kidney fibrosis, another giant, unmet medical need.
Czirr added that Galectin Therapeutics also has a drug for cancer that addresses a very significant need for cancer patients. "Tumors have figured out how to turn off your body's immune system and no one has addressed that issue. That's why we think cancer is such a difficult disease to fight. We believe that in combination with other treatments, our treatment is going to make a big difference for a lot of patients." stated Jim Czirr, Executive Chairman of Galectin Therapeutics.
About Galectin & InterlinedTV
Galectin Therapeutics is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. More information at http://www.galectintherapeutics.com
InterlinkedTV is an internet video production and distribution site dedicated to Entrepreneurs and Investors. We feature education, public and private companies, venture capital news, and investment events. This content is exclusive and cannot be found anywhere else. We give our members and viewers a unique chance to meet the CEOs and executives of high growth companies. More information at InterlinkedTV.com